Cidara Therapeutics Inc (NASDAQ: CDTX) stock enjoyed a major increase of 10.8% on 7/26/24. The shares closed at $13.24. Moreover, trading volume in this advance was unusually high at 158% of normal. The stock has been extremely weak relative to the market over the last nine months but has risen 4.7% during the last week.
Current PriceTarget Research Rating
Reflecting future returns on capital that are forecasted to be in line with the cost of capital, CDTX is expected to continue to be Value Creation neutral.
Cidara Therapeutics is currently unrated.
Rating Review
The stock is currently unrated.
Be the first to comment